The management of Brugada syndrome patients

Folia Cardiologica

Volumn 14, Issue 1, 2007, Pages 97-106

  Pérez Riera, Andrés Ricardo ^a,f   Zhang, Li ^b   Uchida, Augusto Hiroshi ^c   Schapachnik, Edgardo ^d   Dubner, Sergio ^e   Ferreira, Celso ^a,c  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^e Arryhthmias and Electrophysiology Service   (Argentina)

^f ABC Foundation ^*  (Brazil)

Author keywords

Brugada syndrome; Implantable cardioverter defibrillator; Isoproterenol; Quinidine; Radiofrequency ablation

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CEBRALAT; CILOSTAZOL; COCAINE; DENOPAMINE; DIHYDROQUINIDINE; DOBUTAMINE; GLIBENCLAMIDE; GLUCOSE; INSULIN; ISOPRENALINE; QUINIDINE; QUINIDINE ACID SULFATE; SODIUM CHANNEL; SOTALOL; TEDISAMIL; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL HEART PACEMAKER; AUTOPSY; BRUGADA SYNDROME; CARDIOMEGALY; CATHETER ABLATION; DEFIBRILLATOR; DRUG BIOAVAILABILITY; ELECTROCARDIOGRAM; HEART DEPOLARIZATION; HEART REPOLARIZATION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; ION CURRENT; PURKINJE FIBER; RECEPTOR BLOCKING; SINGLE DRUG DOSE; SUDDEN DEATH;

EID: 34247556094     PISSN: 15074145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol, 1987; 253: H704-H708.
2. + channel current by quinidine. Circ Res, 1993; 73: 351-359.
3. Antzelevitch C, Yan GX, Shimizy W, Burashnikov A. Electrical heterogeneity, the ECG, and Cardiac arrhythmias. In. Zipes DP, Jalife J. cardiac electrophysiology from cell to bedside. 3rd Ed. W.B. Saunders Company. 2000; 26: 222-238.
4. Suzuki H, Torigoe K, Numata O et al. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol, 2000; 11: 1277-1280.
5. Gaita F, Giustetto C, Bianchi F et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol, 2004; 43: 1494-1499.
6. Belhassen B, Viskin S, Fish R et al. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol, 1999; 10: 1301-1312.
7. Chen PS. What's new in EP: quinidine is good but fever is bad for Brugada syndrome. J Cardiovasc Electrophysiol, 2000; 11: 126.
8. Alings M, Dekker L, Sadee A et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol, 2001; 24: 1420-1422.
9. Hermida JS, Denjoy I, Clerc J et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol, 2004; 43: 1853-1860.
10. Mok NS, Chan NY, Chi-Suen Chiu A. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol, 2004; 27: 821-823.
11. Anselme F, Frank R. The best of arrhythmia in 2004. Arch Mal Coeur Vaiss, 2005; 98: 57-62.
12. Marquez MF, Rivera J, Hermosillo AG et al. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol, 2005; 28: 870-873.
13. Napolitano C, Priori SG. Brugada syndrome. Orphanet J Rare Dis, 2006; 1: 35.
14. Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J, 2005; 5: 25-34.
15. Probst V, Evain S, Gournay V et al. Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated by hydroquinidine therapy in a 3-year-old child. J Cardiovasc Electrophysiol, 2006; 17: 97-100.
16. Watanabe H, Chinushi M, Washizuka T et al. Variable electrocardiographic effects of short-term quinidine sulfate administration in Brugada syndrome. Pacing Clin Electrophysiol, 2005; 28: 372-377.
17. Hermann HP, Ohler A, Just H et al. Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy. J Cardiovasc Pharmacol, 1998; 32: 969-974.
18. Ohler A, Amos GJ, Wettwer E et al. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for "reverse use dependent" block. Naunyn Schmiedebergs Arch Pharmacol, 1994; 349: 602-610.
19. Tsuchiya T, Ashikaga K, Honda T et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol, 2002; 13: 698-701.
20. Abud A, Bagattin D, Goyeneche R et al. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol, 2006; 17: 210-122.
21. Shimizu W, Aiba T, Antzelevitch C. Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des, 2005; 11: 1561-1572.
22. Asenjo R, Madariaga R, Morris R et al. Sudden death due to recuperated ventricular fibrillation: Brugada syndrome? Rev Med Chil, 1998; 126: 814-821.
23. Miyazaki T, Mitamura H, Miyoshi S et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol, 1996; 27: 1061-1070.
24. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation, 1999; 100: 1660-1666.
25. Shimizu W, Kamakura S. Catecholamines in children with congenital long QT syndrome and Brugada syndrome. J Electrocardiol, 2001; 34: 173-175.
26. Tanaka H, Kinoshita O, Uchikawa S et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol, 2001; 24: 1293-1294.
27. Khan IA, Nair CK. Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease. Ann Noninvasive Electrocardiol, 2004; 9: 280-289.
28. Maury P, Couderc P, Delay M et al. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace, 2004;6: 130-133.
29. Izumida N, Asano Y, Doi S et al. Changes in body surface potential distributions induced by isoproterenol and Na channel blockers in patients with the Brugada syndrome. Int J Cardiol, 2004; 95: 261-268.
30. Takagi A, Nakazawa K, Sakurai T et al. Prolongation of LAS4O (duration of the low amplitude electric potential component (<40 microV) of the terminal portion of the QRS) induced by isoproterenol in 11 patients with Brugada syndrome. Circ J, 2002; 66: 1101-1104.
31. Araújo N, Godinho F, Maciel W et al. Pesquisa de Portadores Assintomáticos da Síndrome de Brugada Através do Teste da Ajmalina e Dobutamina. LIV Congresso Brasileiro de Cardiologia Tema Livre 084 Hospital Universitário Clementino Fraga Filho - UFRJ; Clínica São Vicente Rio de Janeiro-RJ Brasil.
32. Lee KL, Lau CP, Tse HF et al. Prevention of ventricular fibrillation by pacing in a man with Brugada syndrome. J Cardiovasc Electrophysiol, 2000; 11: 935-937.
33. Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol, 1997; 8: 325-31.
34. Brugada J, Brugada P, Brugada R. The syndrome of right bundle branch block ST segment elevation in Vito V3 and sudden death - the Brugada syndrome. Europace, 1999; 1: 156-166.
35. Brugada J, Brugada R, Brugada P. Brugada syndrome Arch Mal Coeur Vaiss, 1999; 92: 847-850.
36. Chalvidan T, Deharo JC, Dieuzaide P et al. Near fatal electrical storm in a patient equipped with an implantable cardioverter defibrillator for Brugada syndrome. Pacing Clin Electrophysiol, 2000; 23: 410-412.
37. Sicouri S, Moro S, Litovsky S et al. Chronic amiodarone reduces transmural dispersion of repolarization in the heart. J Cardiovasc Electrophysiol, 1997; 8: 1269-1279.
38. Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol, 2000; 11: 95-98.
39. Glatter KA, Wang Q, Keating M et al. Effectiveness of sotalol treatment in symptomatic Brugada syndrome. Am J Cardiol, 2004; 93: 1320-1322.
40. Cheng Q, Kirsch GE, Zhang D et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature, 1998; 392: 293-296.
41. Antzelevitch C, Sicuri S, Litovsky et al. Heterogeneity within the ventricular wall: electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ Res, 1991; 69: 1427-1449.
42. + channel activators in cardiac electrophysiology and arrhythmias. Circulation, 1992; 85: 1627-1629.
43. Di Diego JM and Antzelevitch C. Beat-to-beat alternation of transmural dispersion of repolarization underlies ST-T wave alternans that develops during ischemia. PACE, 1999; 22: 4, 251.
44. Di Diego JM, Feiner JM, Moussallem CG et al. Cellular basis for ischemia-induced ST-segment elevation. PACE, 2001; 24: II-599.
45. Schaffer P, Pelzmann B, Bernhart E et al. The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes. Br J Pharmacol, 1999; 128: 1175-1180.
46. Di Diego JM, Antzelevitch C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues: Does activation of ATP-regulated potassium current promote phase 2 reentry? Circulation, 1993; 88: 1177-1189.
47. 2+] induced electrical heterogeneity and extrasystolic activity in isolated canine ventricular epicardium: Phase 2 reentry. Circulation, 1994; 89: 1839-1850.
48. K-ATP activation induce a transmural dispersion of repolarization resulting in ST segment elevation and arrhythmias. PACE, 1997; 20: 1133 (abstract).
49. Priori S, Paganini V, Boccalatte L et al. Idiopathic ventricular fibrillation: from anecdotal reports to a prospective evaluation. G Ital Cardiol, 1995; 25: 149-158.
50. John RM. Sudden cardiac death. Curr Treat Options Cardiovasc Med, 2004; 6: 347-355.
51. Takenaka S, Kusano KF, Hisamatsu K et al. Relatively benign clinical course in asymptomatic patients with Brugada-type electrocardiogram without family history of sudden death. J Cardiovasc Electrophysiol, 2001; 12: 2-6.
52. Capoferri M, Schwick N, Tanner H et al. Incidence of arrhythmic events in patients with implantable cardioverter-defibrillator for primary and secondary prevention of sudden cardiac death. Swiss Med Wkly, 2004; 134: 154-158.
53. McGregor M, Chen J. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making. Can J Cardiol, 2004; 20: 1199-1204.
54. Kyndt F, Probst V, Potet F et al. Novel SCN5A Mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation, 2001; 104: 3081-3086.
55. Maarten P, van den Berg MD, Arthur AM et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovac Electrophysiol, 2001; 12: 630-636.
56. Haghjoo M, Arya A, Heidari A et al. Suppression of electrical storm by oral quinidine in a patient with Brugada syndrome. J Cardiovasc Electrophysiol, 2005; 16: 674.
57. Shimizu W, Aiba T, Antzelevitch C. Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des, 2005; 11: 1561-1572.
58. Brugada P, Brugada R, Antzelevitch et al. The Brugada syndrome. Arch Mal Coeur Vaiss, 2005; 98: 115-122.
59. Ayerza MR, de Zutter M, Goethals M et al. Heart transplantation as last resort against Brugada syndrome. J Cardiovasc Electrophysiol, 2002; 13: 943-944.
60. McGregor M, Chen J. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making. Can J Cardiol, 2004; 20: 1199-1204.
61. Sanders P, Hsu LF, Hocini M et al. Mapping and ablation of ventricular fibrillation. Minerva Cardioangiol, 2004; 52: 171-181.
62. Weerasooriya R, Hsu LF, Scavee C et al. Catheter ablation of ventricular fibrillation in structurally normal hearts targeting the RVOT and Purkinje ectopy. Herz, 2003; 28: 598-606.
63. Haissaguerre M, Extramiana F, Hocini M et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation, 2003; 108: 925-928.
64. Darmon JP, Bettouche S, Deswardt P et al. Radiofrequency ablation of ventricular fibrillation and multiple right and left atrial tachycardia in a patient with Brugada syndrome. J Interv Card Electrophysiol, 2004; 11: 205-209.
65. Yu CC, Tsai CT, Lai LP, Lin JL. Successful radiofrequency catheter ablation of idiopathic ventricular fibrillation presented as recurrent syncope and diagnosed by an implanted loop recorder. Int J Cardiol, 2006; 110: 112-113.